1. Home
  2. MLYS

as 11-21-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Founded: 2019 Country:
United States
United States
Employees: N/A City: RADNOR
Market Cap: 590.3M IPO Year: 2023
Target Price: $30.00 AVG Volume (30 days): 255.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.33 EPS Growth: N/A
52 Week Low/High: $6.06 - $16.91 Next Earning Date: 11-11-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

MLYS Daily Stock ML Predictions

Stock Insider Trading Activity of Mineralys Therapeutics Inc. (MLYS)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Rodman David Malcom MLYS Chief Medical Officer Nov 11 '24 Sell $15.00 5,026 $75,398.04 140,991
Rodman David Malcom MLYS Chief Medical Officer Nov 6 '24 Sell $15.03 25,482 $383,065.81 140,991
Congleton Jon MLYS Chief Executive Officer Oct 11 '24 Sell $13.52 15,271 $206,433.38 895,941
Levy Adam Scott MLYS CFO and Secretary Oct 11 '24 Sell $13.57 10,757 $146,003.69 236,854

Share on Social Networks: